| Identification of cancer-targeted tropomyosin inhibitors and their synergy with microtubule drugs MA Currier, JR Stehn, A Swain, D Chen, J Hook, E Eiffe, A Heaton, ... Molecular cancer therapeutics 16 (8), 1555-1565, 2017 | 51 | 2017 |
| An examination of future scenarios using historical analogy PJ Dortmans, E Eiffe Futures 36 (10), 1049-1062, 2004 | 33 | 2004 |
| Molecular integration of the anti-tropomyosin compound ATM-3507 into the coiled coil overlap region of the cancer-associated Tpm3. 1 M Janco, MJ Rynkiewicz, L Li, J Hook, E Eiffe, A Ghosh, T Böcking, ... Scientific reports 9 (1), 11262, 2019 | 25 | 2019 |
| Synthesis, anti-cancer and anti-inflammatory activity of novel 2-substituted isoflavenes E Eiffe, E Pasquier, M Kavallaris, C Herbert, DSC Black, N Kumar Bioorganic & Medicinal Chemistry 22 (19), 5182-5193, 2014 | 10 | 2014 |
| Ritter reactions of isoflavanols: A facile route to 4-amidoisoflavans G Iskander, K Wood, E Eiffe, EMH Yee, DSC Black, N Kumar Tetrahedron Letters 56 (15), 1941-1943, 2015 | 6 | 2015 |
| 2-substituted isoflavonoid compounds, medicaments and uses E Eiffe, A Heaton, C Walker, AJ Husband US Patent App. 12/666,657, 2011 | 5 | 2011 |
| Functionalised and substituted indoles as anti-cancer agents A Heaton, E Eiffe, N Pottabathini, P Gunning US Patent App. 15/323,694, 2017 | 2 | 2017 |
| Synergistic action of first-in-class anti-tropomyosin compound, ATM-3507 (Anisina) and microtubule targeting inhibitors in pre-clinical models of non-small cell lung cancer (NSCLC) J Stehn, A Mariana, T Failes, V Ashokakumar, E Eiffe, A Heaton, J Hook, ... European Journal of Cancer 1 (69), S116, 2016 | 2 | 2016 |
| Quinazoline compounds and the use thereof in the treatment of cancer E Hardeman, P Gunning, E Eiffe US Patent App. 17/795,515, 2023 | 1 | 2023 |
| Functionalised and substituted carbazoles as anti-cancer agents I James, I Dixon, A Heaton, E Eiffe, P Gunning US Patent App. 15/323,682, 2017 | 1 | 2017 |
| The synthesis of novel, biologically active isoflavone analogues EJ Eiffe UNSW Sydney, 2012 | 1 | 2012 |
| Developing a new melanoma drug JR Stehn, A Stevenson, L Spoerri, SM Daignault, B Gabrielli, E Eiffe, ... Australasian Journal of Dermatology 57, 11-12, 2016 | | 2016 |
| Abstract B27: First-in-class cytoskeletal targeting drug, Anisina, enhances effectiveness of microtubule inhibitors in a preclinical model of neuroblastoma J Stehn, M Currier, D Chen, E Eiffe, A Heaton, J Hook, P Gunning, T Cripe Cancer Research 76 (5_Supplement), B27-B27, 2016 | | 2016 |
| FIRST IN CLASS CYTOSKELETAL TARGETING DRUG, ANISINA, ENHANCES EFFECTIVENESS OF MICROTUBULE INHIBITORS IN A PRECLINICAL MODEL OF NEUROBLASTOMA. J Stehn, M Currier, D Chen, E Eiffe, A Heaton, J Hook, P Gunning, T Cripe CANCER RESEARCH 76, 2016 | | 2016 |
